Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3036656 + bedaquiline
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**GSK3036656 + bedaquiline** is an investigational **oral combination therapy** studied for the treatment of pulmonary tuberculosis (TB). GSK3036656 (also known as ganfeborole) is a first-in-class benzoxaborole small molecule inhibitor of *Mycobacterium tuberculosis* leucyl-tRNA synthetase, thereby blocking protein synthesis and resulting in bactericidal activity[2][5][6]. Bedaquiline is a diarylquinoline small molecule that inhibits mycobacterial ATP synthase, disrupting energy production in *M. tuberculosis*. The combination aims to provide early bactericidal activity, with the potential for a shorter and more tolerable treatment regimen for drug-sensitive and drug-resistant TB[1][5].
- Other names
- ganfeborole + bedaquiline
02
Targets
LeuRS (Leucyl-tRNA synthetase)AtpE (ATP synthase subunit c of Mycobacterium tuberculosis)AtpC (ATP synthase epsilon subunit)
Beyond the preview
Go deeper on GSK3036656 + bedaquiline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3036656 + bedaquiline.